nach oben

Erschienen in:

18.08.2021 | Epidemiology

HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer

verfasst von: Luciana de Moura Leite, Marcelle Goldner Cesca, Monique Celeste Tavares, Debora Maciel Santana, Erick Figueiredo Saldanha, Paula Tavares Guimarães, Daniella Dias Silva Sá, Maria Fernanda Evangelista Simões, Rafael Lima Viana, Francisca Giselle Rocha, Simone Klog Loose, Sinara Figueiredo Silva, Rafaela Pirolli, Camilla Albina Zanco Fogassa, Bruna Raphaeli Silva Mattos, Fernando Augusto Batista Campos, Solange Moraes Sanches, Vladmir Cláudio Cordeiro de Lima, Noam Falbel Pondé

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Knowledge on whether low expressions of HER2 have prognostic impact in early-stage breast cancer (BC) and on its response to current chemotherapy protocols can contribute to medical practice and development of new drugs for this subset of patients, changing treatment paradigms. This study aims to evaluate the impact of HER2-low status on response to neoadjuvant chemotherapy (NACT) and survival outcomes in early-stage HER2-negative BC.

Methods

Records from all BC patients treated with NACT from January 2007 to December 2018 in a single cancer center were retrospectively reviewed. HER2-negative (immunohistochemistry [IHC] 0, + 1, or + 2 non-amplified by in situ hybridization [ISH]) patients were included. HER2-low was defined by IHC + 1 or + 2 ISH non-amplified and HER2-0 by IHC 0. The coprimary objectives were to compare pathological complete response (pCR) and relapse-free survival (RFS) between luminal/HER2-low versus luminal/HER2-0 populations and between triple negative (TNBC)/HER2-low versus TNBC/HER2-0.

Results

In total, 855 HER2-negative patients were identified. The median follow-up was 59 months. 542 patients had luminal subtype (63.4%) and 313 had TNBC (36.6%). 285 (33.3%) were HER2-low. Among luminal patients, 145 had HER2 IHC + 1 (26.8%) and 91 had IHC + 2/ISH non-amplified (16.8%). In TNBC, 36 had HER2 IHC + 1 (11.5%) and 13 had IHC + 2/ISH non-amplified (4.2%). Most patients had locally advanced tumors, regardless of subtype or HER2-low status. For luminal disease, pCR was achieved in 13% of HER2-low tumors versus 9.5% of HER2-0 (p = 0.27). Similarly, there was no difference in pCR rates among TNBC: 51% versus 47% in HER2-low versus HER2-0, respectively (p = 0.64). HER2-low was also not prognostic for RFS, with 5-year RFS rates of 72.1% versus 71.7% (p = 0.47) for luminal HER2-low/HER2-0, respectively, and 75.6% versus 70.8% (p = 0.23) for TNBC HER2-low/HER2-0.

Conclusion

Our data does not support HER2-low as a biologically distinct BC subtype, with no prognostic value on survival outcomes and no predictive effect for pCR after conventional NACT.

Nur mit Berechtigung zugänglich

Goutsouliak K, Veeraraghavan J, Sethunath V et al (2020) Towards personalized treatment for early stage HER2-positive breast cancer. Nat Rev Clin Oncol 17:233–250. https://doi.org/10.1038/s41571-019-0299-9CrossRefPubMed

Cesca MG, Vian L, Cristóvão-Ferreira S et al (2020) HER2-positive advanced breast cancer treatment in 2020. Cancer Treat Rev 88:102033. https://doi.org/10.1016/j.ctrv.2020.102033CrossRefPubMed

Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. https://doi.org/10.1126/science.3798106CrossRefPubMed

Cameron D, Piccart-Gebhart MJ, Gelber RD et al (2017) 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet 389:1195–1205. https://doi.org/10.1016/S0140-6736(16)32616-2CrossRefPubMedPubMedCentral

Delaloge S, Antoine A, Debled M et al (2020) 279MO Divergent evolution of overall survival across metastatic breast cancer (MBC) subtypes in the nationwide ESME real life cohort 2008–2016. Ann Oncol 31:S352–S353. https://doi.org/10.1016/j.annonc.2020.08.381CrossRef

Gianni L, Lladó A, Bianchi G et al (2010) Open-label, phase ii, multicenter, randomized study of the efficacy and safety of two dose levels of pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2–negative metastat. J Clin Oncol 28:1131–1137. https://doi.org/10.1200/JCO.2009.24.1661CrossRefPubMedPubMedCentral

Mass RD, Press MF, Anderson S et al (2005) Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer 6:240–246. https://doi.org/10.3816/CBC.2005.n.026CrossRefPubMed

Fehrenbacher L, Cecchini RS, Geyer CEJ et al (2020) NSABP B-47/NRG oncology phase III randomized trial comparing adjuvant chemotherapy with or without trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and With IHC 1+ or 2. J Clin Oncol Off J Am Soc Clin Oncol 38:444–453. https://doi.org/10.1200/JCO.19.01455CrossRef

Modi S, Park H, Murthy RK et al (2020) Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase Ib study. J Clin Oncol Off J Am Soc Clin Oncol 38:1887–1896. https://doi.org/10.1200/JCO.19.02318CrossRef

10.

Banerji U, van Herpen CML, Saura C et al (2019) Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. Lancet Oncol 20:1124–1135. https://doi.org/10.1016/S1470-2045(19)30328-6CrossRefPubMed

11.

Tarantino P, Hamilton E, Tolaney SM et al (2020) HER2-low breast cancer: pathological and clinical landscape. J Clin Oncol Off J Am Soc Clin Oncol 38:1951–1962. https://doi.org/10.1200/JCO.19.02488CrossRef

12.

Wolff AC, Hammond MEH, Allison KH et al (2018) Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American pathologists clinical practice guideline focused update. J Clin Oncol Off J Am Soc Clin Oncol 36:2105–2122. https://doi.org/10.1200/JCO.2018.77.8738CrossRef

13.

Wolff AC, Hammond MEH, Hicks DG et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: american society of clinical oncology/college of american pathologists clinical practice guideline update. J Clin Oncol 31:3997–4013. https://doi.org/10.1200/JCO.2013.50.9984CrossRefPubMed

14.

Wolff AC, Hammond MEH, Schwartz JN et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131:18–43CrossRefPubMed

15.

Sikov WM, Berry DA, Perou CM et al (2015) Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (. J Clin Oncol Off J Am Soc Clin Oncol 33:13–21. https://doi.org/10.1200/JCO.2014.57.0572CrossRef

16.

Petrelli F, Cabiddu M, Coinu A et al (2015) Adjuvant dose-dense chemotherapy in breast cancer: a systematic review and meta-analysis of randomized trials. Breast Cancer Res Treat 151:251–259. https://doi.org/10.1007/s10549-015-3405-4CrossRefPubMed

17.

Gray R, Bradley R, Braybrooke J et al (2019) Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. Lancet 393:1440–1452. https://doi.org/10.1016/S0140-6736(18)33137-4CrossRef

18.

Schalper KA, Kumar S, Hui P et al (2013) A retrospective population-based comparison of HER2 immunohistochemistry and fluorescence in situ hybridization in breast carcinomas: impact of 2007 American Society of Clinical Oncology/ College of American Pathologists Criteria. Arch Pathol Lab Med 138:213–219. https://doi.org/10.5858/arpa.2012-0617-OACrossRefPubMed

19.

Rossi V, Sarotto I, Maggiorotto F et al (2012) Moderate immunohistochemical expression of HER-2 (2+) without HER-2 gene amplification is a negative prognostic factor in early breast cancer. Oncologist 17:1418–1425. https://doi.org/10.1634/theoncologist.2012-0194CrossRefPubMedPubMedCentral

20.

Schettini F, Chic N, Brasó-Maristany F et al (2021) Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. npi Breast Cancer 7:1. https://doi.org/10.1038/s41523-020-00208-2CrossRef

21.

Lambein K, Van Bockstal M, Vandemaele L et al (2013) Distinguishing score 0 from score 1+ in HER2 immunohistochemistry-negative breast cancer: clinical and pathobiological relevance. Am J Clin Pathol 140:561–566. https://doi.org/10.1309/AJCP4A7KTAYHZSOECrossRefPubMed

22.

Eggemann H, Ignatov T, Burger E et al (2015) Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer. Endocr Relat Cancer 22:725–733. https://doi.org/10.1530/ERC-15-0335CrossRefPubMed

23.

Reinert T, Sartori GP, Souza AAB et al (2021) Abstract PS4–22: Prevalence of HER2-low and HER2-zero subgroups and correlation with response to neoadjuvant chemotherapy (NACT) in patients with HER2-negative breast cancer. Cancer Res. https://doi.org/10.1158/1538-7445.SABCS20-PS4-22CrossRef

24.

Denkert C, Seither F, Schneeweiss A et al (2021) Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol. https://doi.org/10.1016/S1470-2045(21)00301-6CrossRefPubMed

25.

Eiger D, Agostinetto E, Saúde-Conde R, de Azambuja E (2021) The Exciting New Field of HER2-Low Breast Cancer Treatment. Cancers 13

26.

Clifton GT, Hale D, Vreeland TJ et al (2020) Results of a randomized phase IIb trial of Nelipepimut-S + Trastuzumab versus Trastuzumab to prevent recurrences in patients with high-risk HER2 low-expressing breast cancer. Clin Cancer Res 26:2515–2523. https://doi.org/10.1158/1078-0432.CCR-19-2741CrossRefPubMedPubMedCentral

27.

Mittendorf EA, Lu B, Melisko M et al (2019) Efficacy and safety analysis of nelipepimut-s vaccine to prevent breast cancer recurrence: a randomized, multicenter, phase iii clinical trial. Clin Cancer Res 25:4248–4254. https://doi.org/10.1158/1078-0432.CCR-18-2867CrossRefPubMed

28.

Rossi L, McCartney A, Risi E et al (2019) Cyclin-dependent kinase 4/6 inhibitors in neoadjuvant endocrine therapy of hormone receptor-positive breast cancer. Clin Breast Cancer 19:392–398. https://doi.org/10.1016/j.clbc.2019.05.019CrossRefPubMed

29.

Schmid P, Cortes J, Pusztai L et al (2020) Pembrolizumab for early triple-negative breast cancer. N Engl J Med 382:810–821. https://doi.org/10.1056/NEJMoa1910549CrossRefPubMed

Titel: HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer
verfasst von: Luciana de Moura Leite
Marcelle Goldner Cesca
Monique Celeste Tavares
Debora Maciel Santana
Erick Figueiredo Saldanha
Paula Tavares Guimarães
Daniella Dias Silva Sá
Maria Fernanda Evangelista Simões
Rafael Lima Viana
Francisca Giselle Rocha
Simone Klog Loose
Sinara Figueiredo Silva
Rafaela Pirolli
Camilla Albina Zanco Fogassa
Bruna Raphaeli Silva Mattos
Fernando Augusto Batista Campos
Solange Moraes Sanches
Vladmir Cláudio Cordeiro de Lima
Noam Falbel Pondé
Publikationsdatum: 18.08.2021
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 1/2021
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-021-06365-7

Springer Medizin

HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer